50 likes | 326 Views
New Guidelines for Myocardial Ischemia Management. AHA Scientific Statement: Pharmacologic treatment of hypertension in stable angina. I. IIa. IIb. III. A. β-blocker (prior MI), ACEI/ARB (diabetes and/or LV dysfunction), and diuretic
E N D
AHA Scientific Statement: Pharmacologic treatment of hypertension in stable angina I IIa IIb III A β-blocker (prior MI), ACEI/ARB (diabetes and/or LV dysfunction), and diuretic If β-blocker contraindicated or side effects occur, substitute a nonDHP CCB Add long-acting DHP CCB to β-blocker, ACEI/ARB, diuretic regimen if angina or BP remains uncontrolled Target BP is <130/80 mm Hg or <120/80 mm Hg if LV dysfunction is present B B B Rosendorff C et al. Circulation. 2007;115:2761-88.
BP <120/80 mm Hg LDL-C <100 mg/dL Antiplatelet therapy β-Blocker ACEI or ARB A1C <7% Aldosterone blocker (select women) Smoking cessation Heart-healthy eating pattern Regular physical activity Weight management CVD prevention in high-risk women: Class I recommendations Mosca L et al. Circulation. 2007;115:1481-1501.
CVD prevention in high-risk women: Class II recommendations Consider • LDL-C <70 mg/dL (very-high-risk women) • HDL/non-HDL therapy • Omega-3 fatty acid supplementation • Depression referral and treatment Mosca L et al. Circulation. 2007;115:1481-1501.
Optimal patient care in stable CAD: Summary • Establish aggressive treatment goals • Utilize intensive, multifaceted therapy to achieve and maintain treatment goals • Lifestyle modification • Risk factor reduction • Antianginal therapy